Washington, D.C. 20549





Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

August 5, 2019


Allakos Inc.

(Exact name of registrant as specified in its charter)













(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer
Identification No.)

975 Island Drive, Suite 201

Redwood City, California 94065

(Address of principal executive offices, including zip code)

(650) 597-5002

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock, par value $0.001


The Nasdaq Global Select Market







Item 8.01 Other Events.


On August 5, 2019, Allakos Inc. (the “Company”) hosted a conference call and webcast to present detailed results from its Phase 2 trial in Patients with Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits











Phase 2 EG Results Presentation dated August 5, 2019.



















Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.




Allakos Inc.





Date:  August 5, 2019



/s/ Robert Alexander




Robert Alexander




Chief Executive Officer




Slide 1

Developing Therapeutic Antibodies Targeting Allergic, Inflammatory and Proliferative Diseases Phase 2 Eosinophil Gastritis and Gastroenteritis Study Results Aug 5, 2019 Exhibit 99.1

Slide 2

Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the financial position of Allakos Inc. (“Allakos,” the “Company,” “we” or “our”); the generation of future value; business strategy; plans and objectives for future operations; our expectations regarding the potential benefits, activity, effectiveness and safety of our product candidates; our expectations with regard to the initiation, design, timing and results of our clinical studies, preclinical studies and research and development programs, including the timing and availability of data from such studies; our preclinical, clinical and regulatory development plans for our product candidates, including the timing or likelihood of regulatory filings and approvals for our product candidates; the size of the market opportunity for our product candidates in the diseases we are targeting; and our expectations with regard to our ability to acquire, discover and develop additional product candidates and advance such product candidates into, and successfully complete, clinical studies, are forward-looking statements. Allakos has based these forward-looking statements on its estimates and assumptions and its current expectations and projections about future events. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. The forward-looking statements included in this presentation speak only as of the date of this presentation and are subject to a number of risks, uncertainties, and assumptions, including, but not limited to: the Company’s early stages of clinical drug development; the Company’s ability to timely complete clinical trials for, and if approved, commercialize AK002, its lead compound; the Company’s ability to obtain required regulatory approvals for its product candidates; uncertainties related to the enrollment of patients in its clinical trials; the Company’s ability to demonstrate sufficient safety and efficacy of its product candidates in its clinical trials; uncertainties related to the success of later-stage clinical trials, regardless of the outcomes of preclinical testing and early-stage trials; market acceptance of the Company’s product candidates; uncertainties related to the projections of the size of patient populations suffering from some of the diseases the Company is targeting; the Company’s ability to advance additional product candidates beyond AK002; the Company’s ability to obtain additional capital to finance its operations; and other risks described in the “Risk Factors” section included in our periodic filings that we have made and will make with the Securities and Exchange Commission (“SEC”). In addition, Allakos operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for Allakos’s management to predict all risks, nor can Allakos assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements that Allakos may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Allakos does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results or to make changes in Allakos’ expectations, except as required by law. Accuracy of Data: This presentation contains statistical data based on independent industry publications or other publicly available information, as well as other information based on Allakos’s internal sources. We have not independently verified the accuracy or completeness of the data contained in these industry publications and other publicly available information. Accordingly, Allakos makes no representations as to the accuracy or completeness of that data. Additional Information:The Company has filed and will file Current Reports on Form 8-K, Quarterly Reports on Form 10-Q, and Annual Reports on Form 10-K, and other documents with the SEC. You should read these documents for more complete information about the Company. You may get these documents for free by visiting EDGAR on the SEC website at This presentation concerns products that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration. It is currently limited by federal law to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.

Slide 3

Agenda Robert Alexander, PhD Overview 5:00 – 5:15 AM Henrik Rasmussen, MD PhD Results of the ENIGMA Phase 2 Study 5:15 – 5:45 AM Evan Dellon, MD MPH Physician Perspective 5:45 – 5:55 AM Q&A 5:55 AM

Slide 4

Overview Robert Alexander, PhD CEO – Allakos

Slide 5

Executive Summary AK002 met all prespecified primary and secondary endpoints in EG/EGE Randomized, double-blind, placebo-controlled study results showed: 95% reduction in tissue eosinophils vs. placebo +10% (p < 0.0001) 69% treatment response rate vs. placebo 5% (p = 0.0008) 53% decrease in symptom score vs. placebo 24% (p = 0.0012) Strong proof of concept in EoE 13/14 (93%) of patients had eosinophils < 5 /hpf 53% decrease in dysphagia vs. placebo 17% Today’s data builds on robust results in multiple other diseases

Slide 6

Mast Cells and Eosinophils: Effector Cells Central to Initiating and Maintaining Inflammatory Responses Found at the Internal/External Interface of the Body In particular, in tissues and surrounding blood vessels and peripheral nerves Produce a Broad Range of Inflammatory Mediators Vasoactive amines, lipid mediators, proteases, cytokines and chemokines Participate in Acute and Chronic Inflammation Including both innate and adaptive immune responses Key Drivers in Many Serious Diseases Including gastrointestinal, ophthalmic, dermatologic, respiratory, and proliferative diseases MAST CELLS EOSINOPHILS

Slide 7

AK002 Developed to Target Siglec-8 on Mast Cells and Eosinophils Cell Membrane Activating Receptors Activation Siglec-8 Mast cell Eosinophil Inflammatory response AK002 Inhibition Mast cell Eosinophil Inhibition ADCC/Apoptosis AK002

Slide 8

Mast Cells and Eosinophils are Key Drivers of Inflammatory Disease T Cell B Cell Activated B Cell Mast Cell IgE Activation and Recruitment of Other Immune Cells and Tissue Inflammation Macrophage Eosinophil Neutrophil Allergens Smooth Muscle Neuron Epithelium ACUTE AND CHRONIC INFLAMMATION SENSITIZATION Histamine, LTC4, PGD2 and proteases Bronchoconstriction, increased GI motility, pain, itch IL-33 IL- 4 IL-13 IL- 4 IL-13 Tissue damage, fibrosis ECP, MBP, elastase, MMP, TNFa , IL-1b, TGFb IL-5 IL-8 Histamine Substance P IL-6, TNFa

Slide 9

Eosinophils and Mast Cells Play a Significant Role in Many Diseases Mast Cell Activation Syndrome Indolent Systemic Mastocytosis Chronic Urticaria Atopic Dermatitis Eosinophilic Gastritis Eosinophilic Esophagitis Eosinophilic Gastroenteritis Ulcerative Colitis Vernal Keratoconjunctivitis GASTROINTESTINAL DISEASES OPHTHALMIC DISEASES RESPIRATORY DISEASES SKIN DISEASES MULTI-ORGAN DISEASES Atopic Keratoconjunctivitis Asthma Perennial Allergic Conjunctivitis Eosinophilic Asthma Idiopathic Pulmonary Fibrosis Irritable Bowel Syndrome Crohn’s Disease

Slide 10

Eosinophilic Gastrointestinal Diseases (EGIDs) ESOPHAGUS STOMACH DUODENUM/ SMALL INTESTINE Eosinophilic Gastritis (EG) Eosinophilic Esophagitis (EoE) Eosinophilic Gastroenteritis (EGE) = US Prevalence ~20-25K ~25K ~200K EG, EGE, EoE Chronic Eosinophilic Inflammation of the Stomach, Small Intestine, or Esophagus Eosinophils and mast cells are important drivers of disease Symptoms: abdominal pain, nausea, early satiety, loss of appetite, bloating, abdominal cramping, vomiting, diarrhea, and dysphagia No FDA-approved treatment for EG, EGE, or EoE Current standard of care: diet and/or steroids Potential multi-billion dollar market opportunity

Slide 11

Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Phase 2 Study Henrik S. Rasmussen, MD PhD Chief Medical Officer - Allakos

Slide 12

ENIGMA Phase 2 Study Study Design Randomized, double-blind, placebo-controlled study in EG/EGE Active moderate to severe symptoms Biopsy confirmed EG/EGE Stomach: ≥30 eos/high powered field (hpf) in 5 hpfs Duodenum: ≥30 eos/hpf in 3 hpfs 65 Patients – 3 arms 22 patients 0.3, 1.0, 1.0, 1.0 mg/kg 21 patients 0.3, 1.0, 3.0, 3.0 mg/kg 22 patients placebo 4 monthly doses Endpoints assessed two weeks after last dose

Slide 13

Symptoms Assessed Using Proprietary PRO Abdominal pain Nausea Vomiting Early satiety Loss of appetite Abdominal cramping Bloating Diarrhea Developed in accordance with FDA guidance on PRO development Captures the symptoms of EG/EGE patients on a daily basis Measures 8 symptoms each on a scale of 0-10 (Total Symptom Score 80 points): EG/EGE-SQ© Questionnaire

Slide 14

Prespecified Hierarchical Analysis Per Protocol Primary Endpoint Mean percent change in gastrointestinal eosinophil counts from baseline Responder Secondary Endpoint Proportion of patients who have: >75% decrease in tissue eosinophils AND >30% benefit in Total Symptom Score (TSS) Symptoms Secondary Endpoint Mean percent change in TSS from baseline Endpoints designed to show (1) tissue eosinophil depletion, (2) symptom improvement, and (3) that these effects occur in the same individuals

Slide 15

Baseline Characteristics AK002 (n=39) Placebo (n=20) Total (N=59) Age, Median (Range) 43 (18-74) 40 (18-67) 42 (18-74) Female 72% 50% 64% EoE with Dysphagia 38% (15) 50% (10) 42% (25) % of Patients with AEC1 <500 eos/µL 74% 60% 69% % of Patients with AEC1 <1500 eos/µL 95% 95% 95% Mean Baseline Gastrointestinal Eosinophils/hpf 78 75 77 Mean Baseline Gastrointestinal Mast Cells/hpf 64 56 62 Mean Baseline Total Symptom Score (TSS) 34 30 33 1AEC: Blood Absolute Eosinophil Count

Slide 16

Primary Endpoint Met for All AK002 Groups Treatment Arm Baseline Eosinophil Counts / hpf Mean %∆ in Eosinophil Counts p - value High Dose AK002 (n=20) 76 -97% <0.0001 Low Dose AK002 (n=19) 80 -92% <0.0001 Combined AK002 (n=39) 78 -95% <0.0001 Placebo (n=20) 75 +10% -

Slide 17

37 of 39 patients had < 5 eos/hpf Stomach/Duodenal Eos < 5/HPF AK002 Demonstrates Potent Tissue Eosinophil Depletion % of Patients AK002 Placebo (0/20) (37/39)

Slide 18

AK002 Met Patient Reported Symptoms Secondary Endpoint Statistically significant improvements in symptoms observed 1 day after first infusion and maintained throughout the study Treatment Arm Baseline TSS Mean % Change in TSS p - value High Dose AK002 (n=20) 34 -58% 0.0012 Low Dose AK002 (n=19) 35 -49% 0.0150 Combined AK002 (n=39) 34 -53% 0.0012 Placebo (n=20) 30 -24% -

Slide 19

Higher Proportion of Patients with >50% Reduction in TSS on AK002 vs. Placebo Confidential % of Patients Placebo High Dose High/Low Low Dose AK002 EG/EGE-PRO Total Symptom Score: >50% Reduction (3/20) (13/20) (25/39) (12/19)

Slide 20

Improvement Across All Symptoms Measured on AK002 Confidential EG/EGE-PRO Symptom Score AK002 (n=39) Median Score -59% -79% -100% -65% -61% -57% -47% -55% Baseline End of Tx

Slide 21

AK002 Met Treatment Responder Secondary Endpoint Treatment Arm Treatment Responders p - value High Dose AK002 (n=20) 70% 0.0009 Low Dose AK002 (n=19) 68% 0.0019 Combined AK002 (n=39) 69% 0.0008 Placebo (n=20) 5% - Treatment responder defined as: >75% reduction in tissue eosinophil counts AND >30% reduction in symptoms (TSS)

Slide 22

Additional Analyses

Slide 23

Endpoint Sensitivity Analyses Intent to Treat (ITT): All patients randomized (n=65) Includes Per Protocol (n=59) population plus: 2 patients only received 1 dose of drug 1 patient did not complete PRO 3 patients had their daily steroid dose altered Safety evaluated on the ITT population Protocol allowed steroid use: ≤ 10mg daily oral prednisone Must be preexisting prior to screening start and stable throughout screening, baseline and study periods Acute steroid use Premedication before infusion Therapeutically to manage IRR Protocol violation: Increase or decrease in daily steroid amount Acute steroid use across both groups: 28% AK002, 35% placebo Study Population Acute Steroid Use

Slide 24

All Analyses Show Consistent Results Primary and Secondary Endpoint p-values AK002 Dose Groups Placebo High (n=20/16/21) Low (n=19/12/22) High/Low (n=39/28/43) (n=20/13/22) 1° - Tissue Eosinophils % Δ from BL to Day 99 Per Protocol <0.0001 <0.0001 <0.0001 - No Steroids <0.0001 <0.0001 <0.0001 - ITT <0.0001 <0.0001 <0.0001 - 2° - Treatment Responders (Eos Δ >-75% & TSS Δ >-30%) Per Protocol 0.0009 0.0019 0.0008 - No Steroids <0.0001 0.0001 <0.0001 - ITT 0.0008 0.0017 0.0007 - 2° - Total Symptom Score % Δ from BL to End of Study Per Protocol 0.0012 0.0150 0.0012 - No Steroids 0.0016 0.0313 0.0027 - ITT 0.0260 0.1556 0.0359 -

Slide 25

Eosinophilic Esophagitis Patients AK002 (n=15) Placebo (n=10) Total (N=25) Age, Median (Range) 34 (18-68) 34 (21-53) 34 (18-68) Female 67% 40% 56% Mean Baseline Esophageal Eosinophils/hpf 43 79 56 Mean Baseline Esophageal Mast Cells/hpf 28 36 31 Mean Baseline Dysphagia Score 4.0 4.4 4.2

Slide 26

Esophageal Eos < 5/HPF1 Significant Eosinophil Reductions in Patients With EoE % of Patients AK002 Placebo *p <0.0001 * 13 of 14 patients had < 5 eos/hpf (1/9) (13/14) 1Excludes patients with eos < 5/hpf at baseline

Slide 27

Severity of Dysphagia1 Substantial Improvement in Dysphagia Histological and symptomatic improvement provides strong proof of concept in EoE 1All EoE patients with end of treatment dysphagia scores Mean %∆ from BL AK002 (n=12) Placebo (n=8)

Slide 28

Mast Cell Counts Decrease on AK002 Mast Cells in Gastric, Duodenal, and Esophageal Biopsies Baseline Day 99 Mean Peak Cell Count / hpf -17% -26%* -20% -3% +1% -9% *p <0.05 n= 39 39 BL=22, Day 99 = 21 20 20 BL=12, Day 99 = 10 AK002 Placebo

Slide 29

Safety Summary

Slide 30

Safety: Treatment-Emergent AEs in ≥5% of Patients % of Patients, (n) AK002 (n=43) Placebo (n=22) Infusion related reaction 60% (26) 23% (5) Headache 9% (4) 9% (2) Upper respiratory tract infection 9% (4) 9% (2) Urinary tract infection 9% (4) 5% (1) Nausea 7% (3) 14% (3) Fatigue 7% (3) 9% (2) Diarrhea 5% (2) 9% (2) Nasopharyngitis 5% (2) 9% (2) Abdominal pain 2% (1) 9% (2) Dehydration 2% (1) 9% (2) Gastroenteritis viral 2% (1) 9% (2) Pyrexia 2% (1) 9% (2) Sinusitis 2% (1) 9% (2) Cough 0% (0) 9% (2) Influenza 0% (0) 9% (2) White blood cell count increased 0% (0) 9% (2)

Slide 31

Safety Summary Generally well tolerated Most common AE was mild to moderate infusion related reactions (IRR) 60% of AK002 patients vs 23% placebo 93% mild to moderate (flushing, feeling of warmth, headache, nausea, dizziness) Mostly on first infusion, greatly reduced or does not occur on subsequent infusions 1 drug-related serious adverse event, an IRR which recovered within 24 hours with no further sequelae Treatment-emergent SAEs: 9% on AK002, 14% on Placebo No other significant AEs

Slide 32

Open-Label Extension & Next Steps

Slide 33

Extension Study Status 92% of patients elected to enter long-term extension study Current median duration of treatment 3 months Efficacy appears to improve with continued dosing Optimizing dose administration Pre-dose with oral prednisone 1 day prior to first and second AK002 doses No IRRs observed in patients using steroid pre-dose Allows administration of 1mg/kg as first dose Infusion time can be reduced to < 2 hours on second and subsequent doses

Slide 34

EG/EGE and EoE Next Steps Q4 2019/Q1 2020 End of phase 2 meeting Q1 2020 Estimated phase 3 study start eosinophilic gastritis and/or eosinophilic gastroenteritis Q1 2020 Estimated phase 2/3 study start in eosinophilic esophagitis

Slide 35

Evan S. Dellon, MD MPH TITLE:Professor of Medicine, Gastroenterology & Epidemiology Director, Center for Esophageal Diseases and Swallowing Director, CGIBD Biostatistics and Clinical Research Core INSTITUTION:University of North Carolina School of Medicine SPECIALTY:Gastroenterology FOCUS:Epidemiology, pathogenesis, diagnosis, treatment, and outcomes of Eosinophilic Gastrointestinal Disorders Investigator and member of NIH-funded Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) Editorial Board: Clinical Gastroenterology and Hepatology Author/Co-Author: >200 peer reviewed publications Investigator for multiple EGID studies including EoE

Slide 36

Corporate Updates

Slide 37

Strong Balance Sheet and Significant IP Protection Cash, Cash Equivalents and Investments in Marketable Securities as of June 30, 2019 $153.1M Q2 2019 Operating Expenses $20.1M AK002 US patents run until 2035 Lonza currently manufactures AK002

Slide 38

Anticipated Near-term Milestones Q1’20 Phase 3 EG/EGE and EoE Study starts H2’20 Phase 1 Data For subcutaneous AK002 Q4’19/Q1’20 End of Phase 2 Meeting Q1’20 Phase 1 Data in Mast Cell GI H1’20 Phase 2 Extension Data in EG and/or EGE

Slide 39

Experienced Management Team Previous Experience Robert Alexander, PhD Chief Executive Officer CEO, ZS Pharma Director Alta Partners; Business Development, Genentech Adam Tomasi, PhD President & COO CSO & Head of Corporate Development, ZS Pharma Principal Alta Partners, Drug Discovery, Gilead, Cytokinetics Henrik Rasmussen, MD, PhD Chief Medical Officer CMO, ZS Pharma Head of Clinical Development, Medical and Regulatory Affairs, Novo Nordisk Leo Redmond Chief Financial Officer President & CFO, Presidio Pharmaceuticals Senior Director Finance; Genentech Simon Greenwood, PhD Chief Business Officer Director Roche Venture Fund Head Genenfund; Business Development and Research, Genentech Tim Varacek Chief Commercial Officer SVP, Sales and Commercial Operations, ZS Pharma VP, Sales, InterMune Mark Asbury Chief Legal Officer Chief Legal Officer, ZS Pharma, Pharmacyclics Associate General Council, Genentech Ruby Casareno, PhD VP CMC Director, Manufacturing, Portola Director of Process Development and Manufacturing, OncoMed Sally Bolmer, PhD VP, Reg. Affairs and Drug Development Senior Vice President, Development and Regulatory Affairs, Human Genome Sciences Executive Director, Regulatory Affairs, Centocor

Slide 40

Executive Summary AK002 met all prespecified primary and secondary endpoints in EG/EGE Randomized, double-blind, placebo-controlled study results showed: 95% reduction in tissue eosinophils vs. placebo +10% (p < 0.0001) 69% treatment response rate vs. placebo 5% (p = 0.0008) 53% decrease in symptom score vs. placebo 24% (p = 0.0012) Strong proof of concept in EoE 13/14 (93%) of patients had eosinophils < 5 /hpf 53% decrease in dysphagia vs. placebo 17% Today’s data builds on robust results in multiple other diseases

Slide 41